Demographic and baseline clinical features of adolescent tuberculosis cases, Ukraine, 2015–2018 (n=2491)
| Ages 10–14 years | Ages 15–19 years | Ages 10–19 years | |
| Subjects n (row %) | 557 (22.4) | 1934 (77.6) | 2491 (100) |
| Sex | |||
| Female | 280 (50.3) | 901 (46.6) | 1181 (47.4) |
| Male | 277 (49.7) | 1033 (53.4) | 1310 (52.6) |
| HIV status | |||
| Infected, no ART start date documented | 1 (0.2) | 9 (0.5) | 10 (0.4) |
| Infected, not on ART at start of TB treatment | 29 (5.2) | 23 (1.2) | 52 (2.1) |
| Infected, on ART at start of TB treatment | 13 (2.3) | 13 (0.7) | 26 (1.0) |
| Uninfected | 479 (86.0) | 1818 (94.0) | 2297 (92.2) |
| Unknown | 35 (6.3) | 71 (3.6) | 106 (4.3) |
| Urban or rural residence | |||
| Urban | 292 (52.4) | 1137 (58.8) | 1429 (57.4) |
| Rural | 262 (47.1) | 784 (40.5) | 1046 (42.0) |
| Unknown | 3 (0.5) | 13 (0.7) | 16 (0.6) |
| Migration status | |||
| Migrant | 6 (1.1) | 26 (1.3) | 32 (1.3) |
| Nonmigrant | 551 (98.9) | 1908 (98.7) | 2469 (98.7) |
| Oblast | |||
| Conflict-affected | 28 (5.0) | 99 (5.1) | 127 (5.1) |
| Not conflict-affected | 529 (95.0) | 1835 (94.9) | 2364 (94.9) |
| History of alcohol use | |||
| Yes | 0 (0.0) | 17 (0.9) | 17 (0.7) |
| No | 557 (100.0) | 1917 (99.1) | 2474 (99.3) |
| History of incarceration | |||
| Yes | 0 (0.0) | 24 (1.2) | 24 (1.0) |
| No | 557 (100.0) | 1910 (98.8) | 2467 (99.0) |
| Probable source case identified | |||
| Yes | 110 (19.7) | 214 (11.1) | 324 (13.0) |
| No | 447 (80.3) | 1720 (88.9) | 2167 (87.0) |
| Case classification | |||
| New | 537 (96.4) | 1863 (96.3) | 2400 (96.3) |
| Recurrent | 20 (3.6) | 71 (3.7) | 91 (3.7) |
| Diagnosis | |||
| Microbiological | 446 (80.1) | 1756 (90.8) | 2202 (88.4) |
| Clinical | 111 (19.9) | 178 (9.2) | 289 (11.6) |
| Site of disease | |||
| Exclusively intrathoracic | 455 (81.7) | 1824 (94.3) | 2279 (91.5) |
| Exclusively extrathoracic | 85 (15.3) | 66 (3.4) | 151 (6.1) |
| Intra- and extrathoracic | 17 (3.1) | 44 (2.3) | 61 (2.4) |
| Lung cavitation | |||
| Cavitary pulmonary TB | 56 (10.1) | 638 (33.0) | 694 (27.9) |
| Noncavitary pulmonary TB | 264 (47.4) | 1076 (55.6) | 1340 (53.8) |
| No pulmonary TB | 237 (42.5) | 220 (11.4) | 457 (18.3) |
| Pleural TB | |||
| Isolated pleural | 30 (5.4) | 131 (6.8) | 161 (6.5) |
| Pleural+pulmonary | 12 (2.2) | 45 (2.3) | 57 (2.3) |
| No pleural involvement | 515 (92.4) | 1758 (90.9) | 2273 (91.2) |
| Baseline drug resistance profile | |||
| INH- and RIF-susceptible | 379 (68.0) | 1289 (66.6) | 1668 (67.0) |
| INH-monoresistant | 11 (2.0) | 108 (5.6) | 119 (4.8) |
| RR but not pre-XDR | 20 (3.6) | 153 (0.8) | 173 (6.8) |
| RR, no SLD DST | 11 (2.0) | 63 (3.3) | 74 (3.0) |
| Pre-XDR but not XDR | 12 (2.1) | 73 (10.8) | 85 (3.4) |
| XDR | 6 (1.1) | 38 (2.0) | 44 (1.8) |
| No result# | 118 (21.2) | 210 (10.9) | 328 (13.2) |
Data are presented as n (column %), unless otherwise stated. ART: antiretroviral therapy; TB: tuberculosis; INH: isoniazid; RIF: rifampicin; RR: rifampicin-resistant; SLD: second-line drug; DST: drug susceptibility testing; XDR: extensively drug-resistant. #: DST result was not documented in 39 (1.8%) of 2202 microbiologically confirmed cases.